VEGFA and soft tissue sarcoma: Pazopanib is a multiple vascular endothelial growth factor (VEGF) inhibitor approved by the FDA for the treatment of advanced renal carcinoma and advanced soft tissue sarcoma in 2009 and 2012, respectively [55].